Melanie Kelly



Related information

Phone: 902-494-3325
Fax: 902-494-1388
Mailing Address: 
Room 15A3, Sir Charles Tupper Medical Building, 5850 College Street, PO Box 15000, Halifax, Nova Scotia, Canada B3H 4R2
Research Topics:
  • regulation of intraocular pressure
  • retinal neurovascular signaling
  • ocular microcirculation
  • ocular inflammatory diseases (uveitis, uveoretinitis, proliferative vitreoretinopathy)
  • vasculopathies

Research expertise

Dr. Kelly’s primary research expertise is molecular and functional pharmacology with a special interest in translational pharmacology and drug development in the cannabis/cannabinoid space. Dr. Kelly’s lab has research expertise in ocular and central nervous system pharmacology and therapeutics and examines use of drugs that target the endocannabinoid system for neurodegenerative disease and pain and inflammation.


Management, Dalhousie University, Nova Scotia, Canada. Professor Kelly is also the Executive Director of the International Cannabinoid Research Society, a Canadian Consortium for the Investigation of Cannabinoids Board Member and Director and Chief Scientific Officer, Panag Pharma Inc. Halifax, Nova Scotia, Canada. Dr. Kelly’s primary research expertise is in translational pharmacology and drug discovery. Her research specifically addresses the pharmacology of the endocannabinoid system and how cannabis and cannabinoids can modify disease. She has published more than 100 publications in the area of pharmacology, cannabinoids and the endocannabinoid system and holds several patents in the area of cannabinoid drugs for therapeutic management of disease. Professor Kelly has participated in and developed curriculum in medicine and pharmacy at undergraduate and graduate levels as well as content for continuing medical education and postgraduate professional education. She contributes as an expert consultant to industry with regard to drug development in the cannabis/cannabinoid space and in the development of scientific material for public dissemination and knowledge translation. Dr. Kelly’s recent work has focused on development of new therapies to alleviate pain and inflammation. As one of the founders of a small drug company based in Halifax, she is working to leverage research discoveries into Health Canada approved medicines for those suffering from chronic neurodegenerative diseases.